Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Appointed CFO
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Forest Laboratories, LLC (FRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/30/2021 GN Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update
02/11/2021 GN SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Forest Road Acquisition Corp. Merger
11/16/2020 GN Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
09/21/2020 GN Fennec Announces Issuance of U.S. Patent for PEDMARK™
08/12/2020 GN Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
08/11/2020 GN Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
08/05/2020 GN Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
06/26/2020 GN Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
06/22/2020 GN Fennec Announces Results of Annual Meeting
05/14/2020 GN Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update
05/08/2020 GN Fennec Announces Exercise and Closing of Underwriters' Option to Purchase Additional Shares
04/29/2020 GN Fennec Announces Proposed Public Offering of Common Shares
04/13/2020 GN Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™
03/05/2020 GN Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™
02/28/2020 GN Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate
11/12/2019 GN Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results
10/02/2019 GN Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
09/24/2019 GN Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors
09/09/2019 GN Fennec Appoints Shubh Goel as Chief Commercial Officer
06/19/2019 GN Fennec Announces Results of Annual Meeting
02/04/2019 GN Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank
12/20/2018 GN Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™
11/16/2018 GN Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting  
11/13/2018 GN Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results
09/26/2018 GN Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City
08/13/2018 GN Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results
08/07/2018 GN Fennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Authorization
06/21/2018 GN Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine
06/11/2018 GN Fennec Pharmaceuticals Set to Join Russell 3000 Index
06/08/2018 GN Fennec Announces Results of Annual Meeting
05/14/2018 GN Fennec Provides Business Update and Announces First Quarter 2018 Financial Results
03/27/2018 GN Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™
03/26/2018 GN Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results
03/21/2018 GN Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy